Abstract: Ofatumumab may be used in treating multiple sclerosis (MS), wherein the treatment is a long-term treatment and wherein serum IgG level is maintained during the treatment. B cell and/or T cell inhibitors may be used in the treatment of MS, which treatment includes monitoring serum IgG level and selecting ofatumumab as the B cell and/or T cell inhibitor if the serum IgG level decreases and/or the treatment includes assessing the predisposition of the patient for an increased risk of infections and selecting ofatumumab as the B cell and/or T cell inhibitor if a predisposition is identified. Ofatumumab may be used in treating multiple sclerosis, wherein patients having a lowered serum IgG level are treated and/or wherein patients having risk factors associated with serum Ig levels, in particular serum IgG levels, are treated.

Abstract: The disclosure relates to methods of providing a multiple sclerosis (MS) treatment that allows controlling conditions other than MS such as infections.

Abstract: The present invention relates to the anti-CD20 monoclonal antibody ofatumumab for use in the treatment or prevention of relapsing multiple sclerosis, wherein ofatumumab is used in a patient who has been treated with a disease-modifying therapy other than ofatumumab.